Status:

NOT_YET_RECRUITING

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

Lead Sponsor:

Huazhong University of Science and Technology

Conditions:

Femoral Neck Fractures

Femur Head Necrosis

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

The goal of this clinical trial is to study the analgesic effect of liposomal bupivacaine plus bupivacaine for Pericapsular Nerve Group (PENG) block in postoperative pain management following hip repl...

Eligibility Criteria

Inclusion

  • American Society of Anesthesiologists(ASA) I\~II
  • Normal coagulation
  • Clinical diagnosis of hip fracture

Exclusion

  • Presence of severe systemic diseases or ASA grade III or higher
  • Allergy to amide local anesthetics

Key Trial Info

Start Date :

September 15 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06565910

Start Date

September 15 2024

End Date

February 1 2025

Last Update

August 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Anesthesiology, Tongji Hospital, Tongji Medical College, HUST

Wuhan, Hubei, China, 430030

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) | DecenTrialz